New drug shows promise for rare stomach disease

NCT ID NCT03678545

Completed Disease control Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested dupilumab, a drug that calms certain immune reactions, in 41 people aged 12-70 with eosinophilic gastritis, a condition where too many immune cells build up in the stomach lining. Participants received either dupilumab or a placebo injection every two weeks for 12 weeks. The main goal was to see if the drug reduced stomach inflammation compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (a drug that blocks certain immune signals to reduce inflammation)
What this could lead to: If it works, this could point toward a treatment for eosinophilic gastritis, a rare stomach condition causing pain and swelling.
What could go wrong: This is a small, early-phase trial with only 41 people. The drug may not reduce stomach inflammation better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GASTRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Eosinophilic enteropathy eosinophilic gastritis eosinophilic gastroenteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC GASTRITIS EOSINOPHILIC GASTROENTERITIS

Contacts and locations

Locations

Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Northwestern Medicine Digestive Health Center

Chicago, Illinois, 60611, United States
Riley Children's Hospital

Indianapolis, Indiana, 46202, United States
Texas Children's Hospital

Houston, Texas, 77030, United States
The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
University of Colorado Denver and Hospital

Aurora, Colorado, 80045, United States
University of North Carolina School of Medicine

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Utah Hospital

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.